Hellmann:The transformation of ALK is ahead of schedule and will be cheaper than expected
Several large investments are lined up for ALK in 2020, but the new tablet vaccines and clear out of the old portfolio are going so well that the company is ahead of schedule, according to CEO Carsten Hellmann.
There are few, if any, worries about ALK's 2019 accounting report, according to CEO Carsten Hellmann.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
